Intergroup Exemestane Study mature analysis: Overall survival data

Anti-Cancer Drugs

Volumn 19, Issue SUPPL. 1, 2008, Pages

  Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; TAMOXIFEN;

BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE; TAMOXIFEN;

EID: 40949133435     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000277608.23376.bc     Document Type: Conference Paper

References (7)

1. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman R, Jones S, et al. Survival and safety of exemestane vs. tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-570.
2. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271.
3. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrazole alone or in combination with tamoxifen versus tamoxigen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
4. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Eng J Med 2004; 350:1081-1092.
6. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of the ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
7. Boccardo F, Rubagotti A, Puntoni M, Ciuglielmini P, Amoroso D, Fini A, et al. Switching to anastrozole vs. continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. Clin J Oncol 2005; 23:5138-5147.